Tag: Selective MC4 receptor agonist

  • Setmelanotide

    Selective MC4 receptor agonist

    An FDA-approved (2020) selective MC4 receptor agonist (Imcivree) for genetic obesity disorders (POMC, LEPR, PCSK1 deficiency).

    Abstract

    Setmelanotide (Imcivree; RM-493; CAS 920014-72-8; molecular weight 1117.34) is a selective MC4 receptor agonist developed by Rhythm Pharmaceuticals and approved by the FDA in 2020 for chronic weight management in adults and children aged 6 years and older with obesity due to proopiomelanocortin (POMC), leptin receptor (LEPR), or PCSK1 deficiency. The compound is also approved for Bardet-Biedl syndrome obesity (2022). Mechanism is selective MC4 agonism in the hypothalamus, restoring downstream signaling in the leptin-melanocortin pathway disrupted by upstream genetic defects. The drug produces clinically meaningful weight loss in the genetically defined responder populations but minimal effect in non-genetic obesity. Pharmacokinetics: subcutaneous administration daily; plasma half-life approximately 11 hours.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.